Breaking News
Get 40% Off 0
Join +750K new investors every month who copy stock picks from billionaire's portfolios Sign Up Free
Close

Ocuphire Pharma Inc (REXN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ocuphire Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Ocuphire Pharma historical data, for real-time data please try another search
1.810 0.000    0.00%
05/11 - Closed. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 1.720 / 1.920
  • Day's Range: 1.720 - 1.920
Type:  Equity
Market:  United States
Ocuphire Pharma 1.810 0.000 0.00%

Rexahn Pharma Company Profile

 
Get an in-depth profile of Ocuphire Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

14

Equity Type

ORD

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Contact Information

Address 37000 Grand River Avenue Suite 120
Farmington Hills, 48335
United States
Phone (248) 957-9024
Fax -

Top Executives

Name Age Since Title
Cameron S. Gallagher 53 2020 Independent Chairman
George Magrath 40 2023 CEO & Director
Richard J. Rodgers 57 2020 Independent Director
James S. J. Manuso 75 2020 Independent Director
Peter K. Kaiser - 2020 Member of Medical Advisory Board
Susan K. Benton 59 2020 Independent Director
Sean Ainsworth 56 2020 Lead Independent Director
Jay S. Pepose 69 2018 Chief Medical Advisor & Director
David S. Boyer - - Member of Medical Advisory Board
Jeffrey S. Heier 63 - Member of Medical Advisory Board
Charles C. Wykoff - 2024 Member of Medical Advisory Board
David Brown - 2021 Member of Medical Advisory Board
David R. Lally - 2021 Member of Medical Advisory Board
Anat Lowenstein 65 2022 Member of Medical Advisory Board
Rishi P. Singh - 2024 Member of Medical Advisory Board
Caroline R. Baumal 56 2022 Member of Medical Advisory Board
Carl D. Regillo - 2024 Member of Medical Advisory Board
Arshad M. Khanani - 2024 Member of Medical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OCUP Comments

Write your thoughts about Rexahn Pharma
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email